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Introduction
Polycystic ovary syndrome (PCOS) is diagnosed by a combination of oligo-ovulation, clinical and/or biochemical signs of hyperandrogenism, or ultrasound findings consistent with polycystic ovaries (1) . PCOS is associated with metabolic abnormalities, such as dyslipidemia, obesity, and glucose intolerance, which are also components of the metabolic syndrome (MBS). The prevalence of MBS in adult premenopausal women with PCOS is approximately 40% (2) . The prevalence of adolescent females with MBS in the United States is 12.4-44.2% (3). In one study using a national database (4), adolescents with PCOS were found to be at increased risk for MBS in comparison with controls; however, PCOS status could not be accurately ascertained in the control subjects. MBS prevalence in an adolescent PCOS cohort was found to be at least 3-fold higher when adjusted for body mass index (BMI) status (5).
Adults with MBS are at a greater risk of developing cardiovascular disease (6, 7) . Cardiovascular risk is especially pronounced at younger ages in PCOS patients than in women without a history of PCOS (8, 9) . Women with PCOS may be at even greater risk for cardiovascular disease because they are exposed to risk factors at a younger age.
The aims of this study are to establish the prevalence of MBS in obese, adolescent girls with and without PCOS and to examine the prevalence of related characteristics associated with MBS. We sought to determine whether PCOS increases the risk of MBS in obese adolescents. In addition, we analyzed serum markers of cardiovascular disease to determine whether they are elevated in obese adolescents with and without PCOS, and if such measures are independently associated with PCOS.
Subjects and Methods

Subjects and study design
We performed a cross-sectional study of overweight [BMI ≥ 25-29. 9 Subjects Review Board at the University of Rochester and all subjects provided signed consent if they were 18 years of age or older or gave assent with signed consent by parent or legal guardian.
Adolescents were included if they fulfilled the age and weight criteria stated above. Exclusion criteria were pregnancy, diagnosis of diabetes mellitus, other endocrinopathy (congenital adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia), the use of combined oral contraceptive or other medications known to affect gonadal or adrenal function or carbohydrate or lipid metabolism within the 2 months preceding enrollment in the study, tobacco or alcohol use, or a history of ovarian surgery.
We defined MBS as reported by Cook (10) ( Table 1 ) using pediatric criteria. We also used the American Heart Association (AHA) and the National Heart, Lung, and Blood Institute (NHLBI) definition of MBS for adults and the International Diabetes Foundation (IDF) definition for MBS in adolescents (11, 12, 13, 14) (Table 1) . For all definitions the presence of 3 or more criteria resulted in the diagnosis of MBS with the IDF definition requiring an increased waist circumference in addition to 2 other features..
Study Protocol
All subjects who were enrolled in the study had a medical history and underwent physical examination, including determination of Ferriman-Gallwey (FG) scoring of hirsutism. Weight was measured in kilograms and height was measured to the nearest 0.5 centimeter. BMI was calculated.
Blood pressure was measured in the supine position and averaged over 3 measurements. Waist circumference was measured in centimeters via tape measure at the widest point between the lower border of the right costal margin and the top of the iliac crest. With a semi-full bladder the subjects then underwent a trans-abdominal ultrasound examination to visualize the ovaries and uterus and to calculate ovarian volume.
At a separate visit, eligible subjects were studied at the URMC General Clinical Research Center.
Subjects with regular menses were studied in the early follicular phase of the menstrual cycle. hologic, Bedford, Massachusetts) was performed to estimate body fat.
Visceral and subcutaneous adipose tissues were calculated for each PCOS subject using a single image computerized tomography (CT) scan at the L4-L5 vertebral interspace. Tomovision SliceOmatic CT software was used to assign subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT) based upon assigned tissue density.
Assays
After sample collection, sera was extracted and stored at -80 The free androgen index was calculated by the equation: FAI= (testosterone/SHBG) x 100. The areas under the curve (AUC) for glucose and insulin during the OGTT were calculated using the trapezoid rule.
Statistical Analysis
Results are reported as means (standard deviation) unless otherwise stated. All analyses were performed using SAS (Version 9.1; SAS Institute Inc, Cary, NC). Group differences were analyzed using t-tests for continuous variables and Fisher's exact test for categorical values. A one-way ANOVA was used to compare the adolescents by their number of MBS components. Two-tailed P-values <0.05 were considered significant.
Results
Demographics and Anthropometrics
All 43 subjects with diagnosis of PCOS had menstrual abnormalities and clinical evidence of androgen excess with either elevated serum androgens or clinical hirsutism with an elevated FerrimanGallwey score of >6 (15) . A total of 90% of the subjects with PCOS had an elevated total testosterone or free androgen index. Hirsutism was noted in 87.5% of the PCOS adolescents with a range of the FG score between 5-22. Mean menstrual length in 39 PCOS subjects was 92.7 days, plus an additional 4 subjects with amenorrhea of at least one year after initially irregular cycles. Thirty-one adolescent females served as BMI-matched controls. The mean menstrual length in these subjects was 26.9 days. Table 2 demonstrates the ethnic and racial characteristics of the study groups. There were no significant differences in weight, BMI, or percent body fat, although the control subjects were slightly younger.
Endocrine Features
As would be expected with the diagnosis of PCOS, the study group had significantly higher measures of total testosterone and free androgen index. Mean FG score in PCOS subjects was 9.6 + 3.9
versus 3.4 + 1.7 in controls (p<0.0001). Ovarian volume was greater in the PCOS subjects (Table 3) .
Ultrasound in this study was performed by transabdominal route. The significant abdominal adiposity present in the subjects, and need for transabdominal scanning, made Rotterdam morphologic ultrasound criteria for PCO difficult to accurately assess, so morphologic data were not included. There was no significant difference in adiponectin (8.6 + 2.2 mg/L in controls versus 9.7 + 4.4 mg/L in PCOS, p=0.2).
Cardiovascular Risk Variables
There were no significant differences between the PCOS adolescents and the control adolescents in waist circumference, fasting glucose or insulin, blood pressure, components of the cholesterol panel, or CRP. AUC glucose and AUC insulin were significantly greater in the PCOS subjects compared with controls ( Table 4 ). The incidence of impaired fasting glycemia or impaired glucose tolerance, as defined by fasting glucose >100 mg/dL (4 subjects) or 2 hour glucose >140 mg/dL (6 subjects), was 25% in PCOS. The control group had significantly fewer subjects with abnormal glucose tolerance with a single subject with an elevated 2 hour glucose and none with impaired fasting glycemia (p=0.01).
Mean PAI-1 levels were significantly higher in PCOS adolescents compared to controls (52. 
Metabolic Syndrome
With respect to diagnosis of MBS within the range of BMI in the cohort, there was an association between the features of MBS and increasing BMI (r=0.23, p=0.05). Using the pediatric criteria, 55%
control group and 53% of the PCOS group fit the criteria for MBS (Table 5) . The IDF has proposed a definition of metabolic syndrome that has recently been adapted for adolescents and is detailed in Table 1 . 
Visceral Adipose Tissue (VAT)
Within the PCOS cohort, VAT levels were significantly higher in the MBS group (p= 0.0027).
When the numbers of MBS factors are compared, those with 3 or more factors have significantly greater VAT (Table 6) In particular, waist circumference, a measure of abdominal obesity, has increased since 1988, with the greatest increases in older adolescent females (18) . In PCOS, a central fat distribution is more common, with visceral fat predominating over peripheral fat (19) . Obesity, as measured overall by BMI, influences the prevalence of MBS. Our study suggests, when matched for obesity, a diagnosis of PCOS is not associated with increased risk of MBS using either pediatric or adult criteria.
All of the adolescents in the current study were overweight or obese, and those with MBS had greater VAT in the PCOS subset. Specifically, the VAT increased with increasing number of MBS characteristics. We found that VAT was correlated with insulin resistance, consistent with previously A recent study demonstrated no difference in abdominal fat distribution between those with obesity with and without PCOS (24). However, the average BMI was only 28, classifying these women as overweight, not obese and the groups were not matched for age which may influence abdominal rates of MBS in their PCOS subjects compared to a national dataset, although they were not matched on BMI. They also found an increased blood pressure in the PCOS subjects. They demonstrated a relationship between hyperandrogenemia and MBS in the PCOS subjects. The relationship between elevated androgens and hypertension in young PCOS women has also been demonstrated by Chen et al.
(32), even after controlling for age and BMI. The current study and another (33) did not find that MBS was associated with androgen concentration within PCOS or control subjects, both of these studies performed in overweight or obese populations. Our study collected control women directly from a similar population of young women who were of similar weight with documented endocrine and menstrual history. The prior study of MBS in adolescent women (4) was unable to truly assess the endocrine characteristics of the control population as neither menstrual data or androgens were recorded in the database for controls. It is possible that the impact of obesity is a more significant contributor to the prevalence of MBS than endocrine status.
Our data shows that obesity is strongly associated with MBS in adolescent women, whether or not they have PCOS. This is particularly notable in the presence of increased VAT. Adolescents with PCOS demonstrate abnormal insulin secretion and action (34) . There may be an associated pathophysiologic link with obesity, particularly visceral adiposity, and related adipose tissue factors, coagulation abnormalities, or insulin resistance (2) that may independently increase cardiovascular risk.
Another marker of cardiovascular risk is plasminogen activator inhibitor-1. PAI-1 is a glycoprotein may influence vascular function by inhibiting fibrinolysis. Our PCOS subjects had significantly higher levels of PAI-1 than the obese control adolescents and this correlated with androgen levels. This is consistent with previous findings in which PAI-1 activity was increased in obese, adult women (35) and young, lean women with PCOS (36). The hyperglycemia and hyperinsulinemia characteristic of PCOS can also be related to increased PAI-1 activity (37).
Our study was limited by its small sample size. Visceral adiposity was also not measured in the control subjects to validate the relationship of visceral adiposity and MBS outside of the PCOS subset. A potential limitation of the study is the use of the radioimmunoassay for testosterone. We recognize that the reliability of immunoassays for testosterone is reduced in the lower ranges found in adolescent women and this may make it difficult to properly categorize subjects by androgen level only. However, this is unlikely to alter the main conclusions. First, we used the NIH classification for PCOS incorporating clinical as well as biochemical measures. Additionally, in this generally obese population, measure of androgen concentration across both groups, separately and without respect to diagnosis of PCOS, was not associated with diagnosis of metabolic syndrome.
The criteria for MBS in adolescents are not yet validated for outcome measures related to cardiovascular disease. When applying the adult definition for MBS, other studies report as many as 1 in 4 obese teens meet these criteria (12) . While the data are limited, there are reports suggesting that adolescents identified with MBS using these criteria will go on to have increased risk for diabetes mellitus or at increased risk for coronary artery disease in adulthood (38, 39) .
Our data indicate that, in obese adolescents, obesity is a stronger predictor of MBS than is PCOS status. Our data further suggest that the effect of obesity is mainly accounted for by visceral adiposity.
This finding emphasizes the importance of obesity counseling in obese adolescent women to reduce the risks associated with MBS. Further studies are needed to determine relationships between MBS, PCOS, and androgens particularly in the non-obese adolescent cohort. 
